Maravai LifeSciences Holdings, Inc. Class A Common Stock (MRVI) Stock Price

MRVIStock

$9.00+244.08%52W

Market Cap$3.33B

P/E—

PEG Ratio—

Div yield—

Beta0.54

MRVI Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)171.64%

Price vs S&P 500 (4W)19.83%

VGM Score55.29

P/CF (Annual)121.94x

Book Value / Share (Quarterly)$0.79

P/TBV (Annual)13.66x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-40.53%

Cash Flow / Share (Quarterly)$-0.14

Price vs S&P 500 (YTD)147.43%

Gross Margin (TTM)34.89%

Net Profit Margin (TTM)-37.07%

EPS (TTM)$-0.53

10-Day Avg Trading Volume5.65M

EPS Excl Extra (TTM)$-0.53

Revenue Growth (5Y)-8.15%

EPS (Annual)$-0.91

ROI (Annual)-24.43%

Gross Margin (Annual)18.30%

Net Profit Margin (5Y Avg)-23.96%

Cash / Share (Quarterly)$0.27

Revenue Growth QoQ (YoY)8.53%

ROA (Last FY)-16.97%

Revenue Growth TTM (YoY)-3.28%

EBITD / Share (TTM)$-0.74

ROE (5Y Avg)-7.32%

Operating Margin (TTM)-57.52%

Cash Flow / Share (Annual)$-0.28

P/B Ratio7.29x

P/B Ratio (Quarterly)7.87x

Net Income / Employee (Annual)$-300,600

EV / Revenue (TTM)7.66x

Net Interest Coverage (TTM)-14.11x

ROA (TTM)-10.54%

EV / EBITDA (TTM)18.29x

EPS Incl Extra (Annual)$-0.91

Current Ratio (Annual)6.60x

Quick Ratio (Quarterly)2.63x

3-Month Avg Trading Volume3.11M

52-Week Price Return244.08%

EV / Free Cash Flow (Annual)3.16x

Revenue / Employee (TTM)$479,900

Tangible BV / Share (Quarterly)$0.26

P/S Ratio (Annual)8.03x

Asset Turnover (Annual)0.24x

52-Week High$8.87

Operating Margin (5Y Avg)-16.92%

EPS Excl Extra (Annual)$-0.91

CapEx CAGR (5Y)-12.34%

26-Week Price Return182.89%

Quick Ratio (Annual)5.40x

13-Week Price Return88.17%

Total Debt / Equity (Annual)1.52x

Current Ratio (Quarterly)4.05x

Enterprise Value$1.60B

Revenue / Share Growth (5Y)3.13%

Asset Turnover (TTM)0.28x

Book Value / Share Growth (5Y)19.28%

Revenue / Employee (Annual)$427,000

Inventory Turnover (Annual)3.35x

Pretax Margin (Annual)-126.50%

Cash / Share (Annual)$0.85

3-Month Return Std Dev71.55%

Gross Margin (5Y Avg)54.38%

Net Income / Employee (TTM)$-177,900

EBITDA Interim CAGR (5Y)-50.59%

ROE (Last FY)-61.58%

Net Interest Coverage (Annual)-7.67x

EPS Basic Excl Extra (Annual)$-0.91

P/FCF (TTM)190.11x

Receivables Turnover (TTM)7.07x

EV / Free Cash Flow (TTM)38.73x

Total Debt / Equity (Quarterly)0.86x

EPS Incl Extra (TTM)$-0.53

Receivables Turnover (Annual)5.80x

ROI (TTM)-15.72%

P/S Ratio (TTM)7.15x

Pretax Margin (5Y Avg)23.06%

Revenue / Share (Annual)$1.29

Tangible BV / Share (Annual)$0.24

Price vs S&P 500 (52W)225.77%

Year-to-Date Return159.38%

5-Day Price Return46.86%

EPS Normalized (Annual)$-0.91

ROA (5Y Avg)-4.04%

Net Profit Margin (Annual)-70.41%

Month-to-Date Return28.31%

Cash Flow / Share (TTM)$0.75

EBITD / Share (Annual)$-1.47

Operating Margin (Annual)-115.89%

LT Debt / Equity (Annual)1.35x

ROI (5Y Avg)-3.36%

LT Debt / Equity (Quarterly)0.71x

EPS Basic Excl Extra (TTM)$-0.53

P/TBV (Quarterly)24.32x

P/B Ratio (Annual)3.91x

Inventory Turnover (TTM)3.09x

Pretax Margin (TTM)-65.38%

Book Value / Share (Annual)$0.83

Price vs S&P 500 (13W)85.38%

Beta0.54x

P/FCF (Annual)24.60x

Revenue / Share (TTM)$1.41

ROE (TTM)-35.42%

52-Week Low$2.28

vGradeD

gGradeD

mGradeA

vgmGradeC

MRVI Earnings Surprise History

Q2 25-0.08est. -0.07

Q3 25-0.08est. -0.08

Q4 25-0.04est. -0.07

Q1 260.01est. -0.05

Q2 26-0.02est. -0.04

MRVI Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

3.88

3.93

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
MRVIMaravai LifeSciences Holdings, Inc. Class A Common Stock	D	D	A	$9.00
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Maravai LifeSciences Holdings, Inc. Class A Common Stock

Maravai LifeSciences provides critical enabling technologies and services for pharmaceutical and biotechnology companies developing drugs, vaccines, and diagnostics. The company operates through two segments: TriLink, which supplies nucleic acid products including mRNA and oligonucleotides; and Cygnus, which provides biologics safety testing and quality assurance solutions. Its products serve customers throughout drug development, manufacturing, and quality assurance processes.